ABBV vs BIIB
By Alex · Tickerpine
AbbVie Inc. vs Biogen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | ABBV | BIIB |
|---|---|---|
| Price | $253.35 | $216.03 |
| Market cap | $447.62B | $31.89B |
| P/E ratio | 123.6 | 23.3 |
| ROE | — | 7.70% |
| Profit margin | 5.79% | 13.80% |
| Revenue growth | 12.40% | 1.90% |
| Dividend yield | 2.73% | — |
| Beta | 0.31 | 0.18 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
ABBV vs BIIB in plain English
- ABBV is the bigger company — about 14.0× the market cap of BIIB.
- BIIB is cheaper on earnings (P/E 23.3 vs 123.6).
- ABBV is growing revenue faster (12% vs 2%).
- ABBV pays a dividend (2.73%) while the other effectively doesn't.
How would $1,000 have done in each?
ABBV return calculator
See what $1,000 in AbbVie Inc. would be worth today.
BIIB return calculator
See what $1,000 in Biogen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.